This company has been marked as potentially delisted and may not be actively trading. Neuralstem (CUR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CUR vs. NKGN, CLDI, AIM, SRNE, SQZ, GNCAQ, GNCA, ELOX, PRME, and PLXShould you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include NKGen Biotech (NKGN), Calidi Biotherapeutics (CLDI), AIM ImmunoTech (AIM), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), and Protalix BioTherapeutics (PLX). These companies are all part of the "medical" sector. Neuralstem vs. Its Competitors NKGen Biotech Calidi Biotherapeutics AIM ImmunoTech Sorrento Therapeutics SQZ Biotechnologies Genocea Biosciences Genocea Biosciences Eloxx Pharmaceuticals Prime Medicine Protalix BioTherapeutics Neuralstem (NASDAQ:CUR) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends. Which has more volatility & risk, CUR or NKGN? Neuralstem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Do institutionals & insiders have more ownership in CUR or NKGN? 38.3% of Neuralstem shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor CUR or NKGN? In the previous week, Neuralstem's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Overall Sentiment Neuralstem Neutral NKGen Biotech Neutral Is CUR or NKGN more profitable? NKGen Biotech has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. NKGen Biotech's return on equity of 0.00% beat Neuralstem's return on equity.Company Net Margins Return on Equity Return on Assets Neuralstem-39,417.64% -170.51% -110.16% NKGen Biotech N/A N/A -479.36% Which has higher valuation & earnings, CUR or NKGN? Neuralstem has higher revenue and earnings than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuralstem$260K5.49-$4.93MN/AN/ANKGen BiotechN/AN/A-$82.94M-$2.45-0.05 SummaryNeuralstem and NKGen Biotech tied by winning 4 of the 8 factors compared between the two stocks. Get Neuralstem News Delivered to You Automatically Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUR vs. The Competition Export to ExcelMetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43M$281.53M$5.76B$9.75BDividend YieldN/AN/A3.95%4.02%P/E RatioN/AN/A31.4426.39Price / Sales5.49537.74431.83159.31Price / CashN/A22.4437.7559.42Price / Book0.1010.8610.566.59Net Income-$4.93M-$115.81M$3.27B$265.83M Neuralstem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CURNeuralstemN/A$0.68+2.4%N/A-80.7%$1.43M$260K0.006NKGNNKGen BiotechN/A$0.13flatN/A-82.6%$5.96MN/A-0.03N/ACLDICalidi Biotherapeutics1.497 of 5 stars$1.72-42.7%N/A-87.6%$5.21MN/A0.0038Positive NewsHigh Trading VolumeAIMAIM ImmunoTech1.0871 of 5 stars$2.48-1.2%$275.00+10,988.7%-92.8%$1.90M$121K-5.2820SRNESorrento Therapeutics0.6304 of 5 stars$0.00+118.2%N/A-33.3%$1.21M$60.32M0.00800Gap DownSQZSQZ BiotechnologiesN/A$0.03flatN/AN/A$826K$18.16M-0.011,620GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070News CoverageELOXEloxx PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0030PRMEPrime Medicine2.6377 of 5 stars$3.24flat$8.92+175.2%-18.5%$436.02M$4.96M-1.58234PLXProtalix BioTherapeutics3.0231 of 5 stars$1.57+2.6%$15.00+855.4%+72.2%$125.18M$61.95M-12.08200 Related Companies and Tools Related Companies NKGN Alternatives CLDI Alternatives AIM Alternatives SRNE Alternatives SQZ Alternatives GNCAQ Alternatives GNCA Alternatives ELOX Alternatives PRME Alternatives PLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access